Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: The present disclosure relates to nanoparticles for delivering a drug targeting brain cancer, whose surface is modified with a peptide for targeting brain cancer, a preparation method thereof, and a use thereof, and more particularly, to nanoparticles for delivering a drug targeting brain cancer, including porous silicon nanoparticles encapsulating an anticancer drug and a peptide with an ability to target brain cancer cells bound to the surface of the nanoparticles, a preparation method thereof, and a use thereof. The nanoparticles according to the present disclosure can be used as an effective drug delivery system for treating glioblastoma by allowing a conventional anticancer agent exhibiting low tissue specificity and solubility to be specifically delivered to glioblastoma in which a caveolin receptor is overexpressed through the blood-brain barrier to induce a more efficient glioblastoma therapeutic effect.

Abstract: The present disclosure is directed formulations, delivery systems and/or methods of use that have a novel a sustained release multi-phasic concentration pattern that may be used, among other things, for reducing mammographic breast density and/or breast stiffness in warm-blooded animals. For example, the formulation may comprise: the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor to a subject that provides a sustained release multi-phasic concentration pattern in the blood of the subject over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor and improves, among other things, breast tissue stabilization and/or increases of the levels of androgen receptor expression.

Abstract: A liquid ink composition includes a liquid phase and particles suspended in the liquid phase, the particles containing a target pharmaceutical or biological agent. The biological activity of the target pharmaceutical or biological agent is preserved upon suspension of the particles in the liquid phase. The liquid phase is capable of solidifying via a solidification process.

Abstract: Amaranthus hybridus silver nanoparticles can be synthesized by mixing an extract of Amaranthus hybridus with a silver nitrate solution to provide a mixture including Amaranthus hybridus silver nanoparticles. The Amaranthus hybridus silver nanoparticles can have an average particle size ranging from about 45 nm to about 100 nm. The AH-AgNPs can have antifungal properties and can be particularly effective agents against Madurella mycetomatis, for the treatment of eumycetoma.

Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.

Abstract: A hollow mesoporous organic silica nano/microparticle having metal particles deposited thereon, and a method for preparing the same. The method may prepare a spherical nanoparticle by coating a porous organic silica layer on an inorganic silica particle having the metal particles deposited thereon and via selective etching of the layer. In addition, two or more types of metals pre-synthesized together with a magnetic particle, or different shapes of metals may be deposited on the nanoparticle at a target concentration. Thus, the nano/microparticle may be used for a drug delivery matrix, a catalyst, and a photothermal effect.

Abstract: Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.

Abstract: A method of making at least one nanocomposite for surface enhanced Raman spectroscopy (SERS) detection of a target of interest includes forming at least one gold nanorod; coating a silver layer on an outer surface of the gold nanorod; assembling a Raman reporter molecule layer on the coated silver layer, wherein the Raman reporter molecule layer comprises Raman reporter molecules that are detectable by the SERS; coating a thiolated polyethylene glycol (PEG) layer on the assembled Raman reporter molecule layer; and conjugating the coated thiolated PEG layer with molecules of an antibody to make the at least one nanocomposite.

Abstract: The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

Abstract: The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

Abstract: A silver nanoparticle composition for controlling or inhibiting the growth of P. jirovecii can include biosynthesized silver nanoparticles and an extract of Farsetia aegyptiaca (FA). The biosynthesized silver nanoparticles can be Farsetia aegyptiaca silver nanoparticles (Fa-AgNPs) prepared using an extract of Farsetia aegyptiaca (FA). In an embodiment, the Farsetia aegyptiaca silver nanoparticles (Fa-AgNPs) can have particle sizes ranging from about 10 nm to about 35 nm.

Abstract: A method of fabricating an extended release subcutaneous medicinal dosage implant system which includes an implant fabricated from a highly homogeneously mixed composition including a medicinal agent in combination with release controlling polymers which include poly (DL-lactide) and polycaprolactone. In one implementation for treating an opioid disease, the formulation composition includes naltrexone at 40 weight percent, poly (DL-lactide) in the approximate range between 36 and 46.4 weight percent, and polycaprolactone in the approximate range between 24 and 11.6 weight percent. In addition, in order to provide anti-biofouling quality and prevent foreign body adsorption/interaction with the material of the implant, polyethylene glycol is added in a preferred content of 2.0%. The manufacturing process includes hot melt extrusion and a mini jet based implant formation stage with the optimized process space were the temperature of the process ranges from 170° C.-180° C.

Abstract: The disclosure provides, methods for preparing scavenging particles, as well as methods for attaching capture agents to the particles. The disclosure further provides compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: Disclosed herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.

Abstract: One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface.

Abstract: An improved low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, a preparation method thereof, and a topical sustained release drug delivery formulation including the same are provided.

Abstract: The composition comprises a polyol crosslinked with a) a multifunctional epoxide; or b) an epihalohydrin; or c) a molecule or crosslinker mixture comprising multiple epihalohydrin and/or epoxide groups or molecules. The composition has a number N1 of effective ether crosslinks per crosslinker molecule as calculated by subtracting 1 from the average number of distinct polyol repeat units bound per crosslinker molecule. The remaining reactive groups on the crosslinker are ineffective in crosslinking and provide a number N2 of pendant groups per crosslinker molecule. Among the N2 groups per crosslinker there are N3 groups per crosslinker that are unreacted or otherwise retain reactivity against nucleophiles. The relationship between N1 and N2 is: N1>0.35 (N1+N2).

Abstract: Amaranthus hybridus silver nanoparticles can be synthesized by mixing an extract of Amaranthus hybridus with a silver nitrate solution to provide a mixture including Amaranthus hybridus silver nanoparticles. The Amaranthus hybridus silver nanoparticles can have an average particle size ranging from about 45 nm to about 100 nm. The AH-AgNPs can have antifungal properties and can be particularly effective agents against Madurella mycetomatis, for the treatment of eumycetoma.

Abstract: Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.